An Efficacy and Safety Study of LYC-30937-EC in Subjects With Moderate Chronic Plaque-type Psoriasis

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

33 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-12-05

Study Completion Date

2017-06-22

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of this Phase 2 trial is to determine the efficacy and safety of LYC-30937-EC in patients with moderate plaque-type psoriasis.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study To Evaluate Safety And Efficacy Of PF-06700841 In Subjects With Moderate To Severe Plaque Psoriasis

NCT02969018

Chronic Plaque Psoriasis

COMPLETED PHASE2

Safety and Efficacy Study of a Novel Ointment to Treat Plaque Type Psoriasis

NCT01029405

Psoriasis

COMPLETED PHASE2

Topical CP-690,550 For Chronic Plaque Psoriasis

NCT00678561

Psoriasis

COMPLETED PHASE2

A First in Human Study to Evaluate Safety, Tolerability, and Pharmacology of PF-06826647 in Healthy Subjects and Subjects With Plaque Psoriasis

NCT03210961

Plaque Psoriasis

COMPLETED PHASE1

A Phase 3 Study in Moderate-to-Severe Plaque Psoriasis With Piclidenoson to Study Safety and Efficacy

NCT06643260

Plaque Psoriasis

NOT_YET_RECRUITING PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Approximately 30 subjects will be enrolled in this double-blind, placebo-controlled study. The randomization will be stratified 2:1 into the LYC-30937-EC cohort (2) or the placebo cohort (1). The active cohort will receive LYC-30937-EC 25 mg once daily, which demonstrated safety and tolerability in Phase I trials.

The study is designed for patients with previously diagnosed moderate chronic plaque-type psoriasis and consists of the following:

* Screening period (initials assessment and eligibility scoring)
* Day 1: confirm eligibility, baseline efficacy assessments (PASI, IGA), randomize and initiate dosing
* Week 2: safety assessments including vital signs, body temperature, physical exam, clinical labs will be performed
* Week 4: efficacy (PASI, IGA) and safety assessments including vital signs, body temperature, physical exam, and clinical labs will be performed
* Week 8: efficacy (PASI, IGA) and safety assessments including vital signs, body temperature, physical exam, and clinical labs will be performed
* Week 12: final efficacy assessments (PASI, IGA), safety assessments including vital signs, body temperature, physical exam, ECG, and clinical labs will be performed
* Week 14: final safety assessments including vital signs, body temperature, and clinical labs

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Psoriasis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

LYC-30937-EC 25 mg PO once daily (QD)

LYC-30937-EC 25 mg by mouth once daily for 12 weeks

Group Type EXPERIMENTAL

Drug: LYC-30937-EC

Intervention Type DRUG

Matching Placebo PO QD

Placebo enteric coated (EC) by mouth once daily for 12 weeks

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Drug: LYC-30937-EC

Intervention Type DRUG

Placebo

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Have a diagnosis of plaque-type psoriasis for at least 6 months prior to screening.
* Must have chronic moderate plaque-type psoriasis confirmed at both screening and baseline visits. Moderate plaque-type psoriasis is defined as a PASI \> 7, with body surface area (BSA) involvement 5-15% inclusive and overall lesion severity of "moderate" or "marked, " where "moderate" = plaque elevation (0.75mm), moderate red coloration, coarse scale predominates; "marked" = moderate plaque elevation (1.0mm), bright red coloration, and thick, non-tenacious scale predominates.
* Female subjects of childbearing potential must agree to use two highly effective forms of contraception during study participation and for 30 days after their last dose of treatment of study drug treatment.
* Male subjects with partners of childbearing potential must take appropriate precautions to avoid fathering a child while participating in the study and use appropriate barrier contraception or abstinence during the study and for 30 days after their last dose of study drug.
* Agree to avoid prolonged sun exposure and avoid tanning booths or ultraviolet (UV) light sources during the study.
* Ability to provide written informed consent and to be compliant with the schedule of events.

Exclusion Criteria

* Non-plaque-type psoriasis (eg, pustular, erythrodermic, and guttate psoriasis).
* Drug-induced psoriasis (ie, new onset or current exacerbation from beta-blockers, calcium channel blockers, or lithium).
* Spontaneously improving or rapidly deteriorating plaque psoriasis.
* Comorbid psoriatic arthritis that is not amenable to treatment with NSAIDs.
* Treatment with a biologic agent for psoriasis.
* Failed 2 or more systemic treatments for plaque psoriasis.
* Received phototherapy or prolonged sun exposure or use of tanning booth or other ultraviolet light source within 4 weeks of initiating screening procedures.
* Received systemic drug therapy (non-biologic) for plaque psoriasis or any systemic medication that could affect psoriasis or its evaluation (PASI or IGA), including but not limited to oral or injectable corticosteroids, retinoids, sulfasalazine, within 4 weeks of initiating screening procedures.
* Received topical medication that could affect psoriasis or its evaluation (PASI or IGA), including but not limited to corticosteroids, retinoids, topical vitamin D derivatives, pimecrolimus, tacrolimus, calcipotriene, within 2 weeks of initiating screening procedures.
* Received immunosuppressant agents (eg, cyclosporine, azathioprine, methotrexate) within 8 weeks of initiating screening procedures.
* Any of the following laboratory abnormalities:

1. liver function tests \> 1.5 x the upper limit of normal (ULN) or direct bilirubin \> 1.5 x ULN
2. hemoglobin \< 8.5 g/dl (international system units \[SI\]: \< 85 g/L)
3. neutrophils \< 1500/mm3 (SI: \< 1.5 x 109/L)
4. white blood cell (WBC) count \< 3,000/mm3 (SI: \< 3.0 x 109/L)
5. platelets \< 80,000 mm3 (SI: 80 x 109/L)
6. international normalized ratio (INR) \> 1.5
7. serum creatinine \> 1.4 mg/dL for women or \> 1.6 mg/dL for men
* Clinically relevant hepatic, neurological, pulmonary, dermatological, ophthalmological, gastrointestinal, endocrine, psychiatric, or other major systemic disease making implementation of the protocol or interpretation of the study difficult or that would put the subject at risk by participating in the study.
* History of or currently active primary or secondary immunodeficiency.
* Treatment with an investigational agent within 30 days prior to initiating screening procedures.

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No